Pfizer, Moderna earns billions of dollars from an enhanced injection
Pharmaceutical companies produce two Vaccine Covid-19 Pfizer and Moderna scheduled to collect billions of dollars from the third injections.
According to analysts and investments in health sectors, Pfizer Ph's Pharmaceutical Firm and the German partner Biontech and Moderna closed more than $ 60 billion in revenue from vaccines in just two 2021 and 2022. Agreements with
Analysts forecast Pfizer / Biontech and Moderna will achieve revenue of more than 6.6 billion USD and USD 7.6 billion in 2023, mainly from sales of vaccine doses for enhanced nasal injections.
Pfizer's Covid-19 vaccine vial at a vaccination center in Geneva, Switzerland, on 3/2.
Moderna early this month said their Covid-19 vaccine achieved 93% from 4 to 6 months after the second nose.
However, more research is needed to determine whether the effectiveness of the Covid-19 vaccine is affected by the age or health condition of the person who is vaccinated.
Incorporating Vaccine Covid-19 Increasing is still a controversial problem because it is unclear how many people need to inject and the frequency.
The World Health Organization (WHO) means that countries do not have to rush to increase the dose to ensure the supply of vaccines for poorer countries.
Comments
Post a Comment